TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07005154: A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer

Sponsor: Astellas Pharma Global Development, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 218 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07005154 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07005154 Rescue Dossier →